News

Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia

Dr. Amor and collaborators have published a new article in the Diabetes Research and Clinical Practice journal using our plasma metabolomics analysis. The aim of the study was to evaluate the role of plasma metabolomics in atherosclerosis according to the presence of type 1 diabetes (T1D) or previous preeclampsia. They have concluded that plasma metabolomics… Read More »Nuclear magnetic resonance-based metabolomic analysis in the assessment of preclinical atherosclerosis in type 1 diabetes and preeclampsia

Biosfer Teslab’s Internacionalization

Biosfer Teslab has received from the Cambra de comerç de Reus an Xpande Digital 2020:  a competitive call for international digitization! This action is co-financed with FEDER funds (European Regional Development Fund) from the European Union. This call is aimed to support the digitization of SMEs, as part of its international strategy, whose main objective… Read More »Biosfer Teslab’s Internacionalization

From LAB to market

Last year we published 19 scientific articles in international journals. We are a metabolomics company halfway between research and clinical practice, a scientific research group in a business environment that is committed to translational research. We carry out scientific collaborations with research groups from universities, research institutions, hospitals and companies in the biomedical sector both… Read More »From LAB to market

Biosfer was awarded with the INNOWWIDE: a high competitive European call

Recently our CEO, Núria Amigó, was invited to participate in the first INNOWWIDE Focus Group, a virtual meeting organized by Steinbeis 2i innovative + international, as an INNOWWIDE funding recipient representative, to evaluate the call impact and to get insight the entire process, enabling to see those activities which we were good at and those… Read More »Biosfer was awarded with the INNOWWIDE: a high competitive European call

GlycA as a new biomarker in rheumatoid arthritis

The research group in Immunology at the University of Oviedo with the participation of Dr. Javier Rodríguez-Carrio has published a study in which one of the variables from our glycoprotein test has been identified as an emerging biomarker for stratification and decision-making in early-stage rheumatoid arthritis. If you want to know more about this publication,… Read More »GlycA as a new biomarker in rheumatoid arthritis

Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles

Our lipoprotein profile, Liposcale (CE), in Cardiovascular Diabetology: “Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles” The research groups of Sant Pau and Hospital Clinic lead by Dr. Didac Mauricio, Dr. Emilio Ortega and Dr. Antonio Amor have published a relevant study including more than 500 type 1 Diabetic… Read More »Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles

Our Liposcale test in clinical practice

We are very happy to announce that the Spanish Arteriosclerosis Society has drawn up a consensus on the clinical use of Nuclear Magnetic Resonance for the study of lipoproteins using our Liposcale® test. The Liposcale® test is an advanced lipoprotein analysis which detects the alterations that predispose to cardiovascular disease. Liposcale test allows a preventive… Read More »Our Liposcale test in clinical practice

We are virtually at the European Arteriosclerosis Society congress

This week the 88th edition of the Congress of the European Arteriosclerosis Society was held in virtual format. The congress has included a large number of basic and clinical research presentations by members of the scientific community. Our research team has participated with the presentation of two Science at a Glance and a poster in… Read More »We are virtually at the European Arteriosclerosis Society congress

A Global Meeting for a Safer World

COVID-19 Hackathon #Endocrine Disruption, #Text mining in #Toxicology, #Bioinformatics #Metabolomics for #biomarker #discovey, #Organ-on-Chip testing… and more We have participated in the #OpenTox Virtual conference: https://www.opentox.net/events/virtual-conference-2020/program Our poster

Predicting the future of health

Once infected by SARS-CoV-2, would you like to know your health status evolution?   This is Biosfer Teslab commitment in the SARS-CoV-2 pandemic. The Spanish Institute of Health Research Pere Virgili, Fundación Alcorcón University Hospital, SCIENCE&STRATEGY SL, Laboratorios Rubió SA, and Biosfer Teslab together with Treat systems (Denmark), Kinesys Consulting (UK), EuroCrime (Italy) have built… Read More »Predicting the future of health